加拿大卫生部批准DARZALEX与来那度胺和地塞米松联合用于不适合移植的初治多发性骨髓瘤患者

2019-10-31 Allan MedSci原创

强生公司近日宣布,加拿大卫生部最近根据优先审评原则批准了DARZALEX(daratumumab)与来那度胺和地塞米松(Rd)联合用于不适合自体干细胞移植(ASCT)的初治多发性骨髓瘤患者。

强生公司近日宣布,加拿大卫生部最近根据优先审评原则批准了DARZALEXdaratumumab)与来那度胺和地塞米松(Rd)联合用于不适合自体干细胞移植(ASCT)的初治多发性骨髓瘤患者。该批准是基于《新英格兰医学杂志》上发表的MAIA III临床研究的最新结果,该研究表明,与仅使用Rd治疗相比,DARZALEX-Rd组合可将疾病进展或死亡风险降低44%。

多发性骨髓瘤(Multiple myeloma, MM,)是一种浆细胞不正常增生,致使侵犯骨髓的一种恶性肿瘤。多发性骨髓瘤一开始多半没有症状,若病情加重时,会有骨痛、感染、贫血等症状。每天大约有9名加拿大人被诊断出患有多发性骨髓瘤。


原始出处:

http://www.firstwordpharma.com/node/1677450#axzz63qZhPxYq

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890069, encodeId=333118900692a, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 27 02:46:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771545, encodeId=c60f1e715456c, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Tue Jan 21 03:46:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312627, encodeId=10e1131262eeb, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441417, encodeId=3aa6144141eb8, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5708, encryptionId=30725e0819, topicName=Darzalex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dad84828862, createdName=12498b37m73暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443352, encodeId=7ab41443352c2, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374662, encodeId=24793e4662c5, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Fri Nov 01 05:48:24 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374650, encodeId=d9913e46506f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Oct 31 21:33:09 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374641, encodeId=37063e464189, content=学习了谢谢分, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Oct 31 18:13:57 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2020-02-27 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890069, encodeId=333118900692a, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 27 02:46:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771545, encodeId=c60f1e715456c, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Tue Jan 21 03:46:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312627, encodeId=10e1131262eeb, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441417, encodeId=3aa6144141eb8, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5708, encryptionId=30725e0819, topicName=Darzalex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dad84828862, createdName=12498b37m73暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443352, encodeId=7ab41443352c2, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374662, encodeId=24793e4662c5, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Fri Nov 01 05:48:24 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374650, encodeId=d9913e46506f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Oct 31 21:33:09 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374641, encodeId=37063e464189, content=学习了谢谢分, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Oct 31 18:13:57 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1890069, encodeId=333118900692a, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 27 02:46:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771545, encodeId=c60f1e715456c, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Tue Jan 21 03:46:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312627, encodeId=10e1131262eeb, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441417, encodeId=3aa6144141eb8, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5708, encryptionId=30725e0819, topicName=Darzalex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dad84828862, createdName=12498b37m73暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443352, encodeId=7ab41443352c2, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374662, encodeId=24793e4662c5, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Fri Nov 01 05:48:24 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374650, encodeId=d9913e46506f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Oct 31 21:33:09 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374641, encodeId=37063e464189, content=学习了谢谢分, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Oct 31 18:13:57 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1890069, encodeId=333118900692a, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 27 02:46:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771545, encodeId=c60f1e715456c, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Tue Jan 21 03:46:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312627, encodeId=10e1131262eeb, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441417, encodeId=3aa6144141eb8, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5708, encryptionId=30725e0819, topicName=Darzalex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dad84828862, createdName=12498b37m73暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443352, encodeId=7ab41443352c2, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374662, encodeId=24793e4662c5, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Fri Nov 01 05:48:24 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374650, encodeId=d9913e46506f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Oct 31 21:33:09 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374641, encodeId=37063e464189, content=学习了谢谢分, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Oct 31 18:13:57 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1890069, encodeId=333118900692a, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 27 02:46:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771545, encodeId=c60f1e715456c, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Tue Jan 21 03:46:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312627, encodeId=10e1131262eeb, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441417, encodeId=3aa6144141eb8, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5708, encryptionId=30725e0819, topicName=Darzalex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dad84828862, createdName=12498b37m73暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443352, encodeId=7ab41443352c2, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374662, encodeId=24793e4662c5, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Fri Nov 01 05:48:24 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374650, encodeId=d9913e46506f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Oct 31 21:33:09 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374641, encodeId=37063e464189, content=学习了谢谢分, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Oct 31 18:13:57 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1890069, encodeId=333118900692a, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 27 02:46:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771545, encodeId=c60f1e715456c, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Tue Jan 21 03:46:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312627, encodeId=10e1131262eeb, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441417, encodeId=3aa6144141eb8, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5708, encryptionId=30725e0819, topicName=Darzalex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dad84828862, createdName=12498b37m73暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443352, encodeId=7ab41443352c2, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374662, encodeId=24793e4662c5, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Fri Nov 01 05:48:24 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374650, encodeId=d9913e46506f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Oct 31 21:33:09 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374641, encodeId=37063e464189, content=学习了谢谢分, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Oct 31 18:13:57 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2019-11-01 yjs木玉

    好好好好好好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1890069, encodeId=333118900692a, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 27 02:46:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771545, encodeId=c60f1e715456c, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Tue Jan 21 03:46:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312627, encodeId=10e1131262eeb, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441417, encodeId=3aa6144141eb8, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5708, encryptionId=30725e0819, topicName=Darzalex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dad84828862, createdName=12498b37m73暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443352, encodeId=7ab41443352c2, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374662, encodeId=24793e4662c5, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Fri Nov 01 05:48:24 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374650, encodeId=d9913e46506f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Oct 31 21:33:09 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374641, encodeId=37063e464189, content=学习了谢谢分, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Oct 31 18:13:57 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2019-10-31 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1890069, encodeId=333118900692a, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 27 02:46:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771545, encodeId=c60f1e715456c, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Tue Jan 21 03:46:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312627, encodeId=10e1131262eeb, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441417, encodeId=3aa6144141eb8, content=<a href='/topic/show?id=30725e0819' target=_blank style='color:#2F92EE;'>#Darzalex#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5708, encryptionId=30725e0819, topicName=Darzalex)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dad84828862, createdName=12498b37m73暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443352, encodeId=7ab41443352c2, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat Nov 02 01:46:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374662, encodeId=24793e4662c5, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Fri Nov 01 05:48:24 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374650, encodeId=d9913e46506f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Oct 31 21:33:09 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374641, encodeId=37063e464189, content=学习了谢谢分, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Oct 31 18:13:57 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2019-10-31 一个字-牛

    学习了谢谢分

    0

相关资讯

多发性骨髓瘤治疗:Kyprolis与Darzalex的组合在III期试验中达到了主要终点

Amgen近日公布的III期临床试验(CANDOR研究)结果显示,与单独使用抗癌药物Kyprolis(卡非佐米)联合地塞米松方案相比,Kyprolis与地塞米松联合强生公司的Darzalex(daratumumab)的三药方案治疗复发难治多发性骨髓瘤患者,能够显著延长无进展生存期(PFS)。

2019 ASCO:Janssen抗CD38单抗Darzalex治疗多发性骨髓瘤III期数据喜人

Janssen Oncology在今年的芝加哥美国临床肿瘤学会(ASCO)年会上公布了抗CD38单抗Darzalex(daratumumab)治疗多发性骨髓瘤的关键数据。

美国FDA批准CD38单抗Darzalex联合疗法,用于可移植的多发性骨髓瘤

强生与Genmab公司宣布,FDA已扩大其CD38单抗Darzalex(daratumumab)的标签范围,使其与硼替佐米、沙利度胺和地塞米松联合,用于新诊断为多发性骨髓瘤且适合自体干细胞移植(ASCT)的患者。

强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤

强生制药公司今天宣布向美国食品和药物管理局(FDA)提交生物制剂许可证申请(BLA),寻求批准其DARZALEX(daratumumab)皮下制剂,用于治疗多发性骨髓瘤患者。

苏格兰医药联盟积极推荐Darzalex作为多发性骨髓瘤的二线治疗方案

强生公司近日宣布,苏格兰医药联盟(SMC)积极推荐使用Darzalex®(daratumumab,达雷妥尤单抗)联合硼替佐米和地塞米松作为多发性骨髓瘤的二线治疗方案。

2018年ASH年会:Darzalex显著降低初治型多发性骨髓瘤患者的疾病进展风险和死亡率

在2018年美国血液学会(ASH)年会上提交的MAIA研究结果显示,将Darzalex(daratumumab)添加到来那度胺和地塞米松方案中显著降低了不适合进行自体干细胞移植的多发性骨髓瘤患者的疾病进展风险或死亡风险。